JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer

Cell Cycle

Volumn 10, Issue 15, 2011, Pages 2583-2591

  Zerbini, Luiz Fernando ^a,b   De Vasconcellos, Jaíra Ferreira ^b   Czibere, Akos ^b   Wang, Yihong ^c   Paccez, Juliano D ^a   Gu, Xuesong ^b   Zhou, Jin Rong ^d   Libermann, Towia A ^b  

^a International Center for Genetic Engineering and Biotechnology (ICGEB)   (South Africa)

^b Beth Israel Deaconess Medical Center Genomics and Proteomics Center   (Israel)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AP 1; Apoptosis; GADD45 family; JunD; Prostate cancer

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45ALPHA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45GAMMA; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR JUND; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH;

EID: 79961123794     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.15.16057     Document Type: Article

References (50)

1. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24:3847-52; PMID: 15750627; DOI: 10.1038/sj.onc.1208518.
2. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-8; PMID: 16254181; DOI: 10.1126/science.1117679.
3. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57:4997-5000; PMID: 9371490.
4. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1:59; PMID: 14691534; DOI: 10.1371/journal.pbio.0000059.
5. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 2002; 13:1-11; PMID: 11801526.
6. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004; 64:8867-75; PMID: 15604246; DOI: 10.1158/0008-5472.CAN-04-2938.
7. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57:141-6; PMID: 8988055.
8. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38:199-207; PMID: 10068344; DOI: 10.1002/(SICI)1097-0045(19990215)38: 3⟨199::AID-PROS4⟩3.0.CO;2-H.
9. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45:542-9; PMID: 7879350; DOI: 10.1016/S0090-4295(99)80034-X.
10. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41:127-33; PMID: 10477909; DOI: 10.1002/(SICI)1097- 0045(19991001)41:2⟨127::AIDPROS7⟩3.0.CO;2-H.
11. Alcover J, Filella X, Luqué P, Molina R, Izquierdo L, Augé JM, et al. Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res 2010; 30:4369-72; PMID: 21036766.
12. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159:2159-65; PMID: 11733366; DOI: 10.1016/S0002-9440(10)63067-2.
13. Andela VB, Gordon AH, Zotalis G, Rosier RN, Goater JJ, Lewis GD, et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 2003; 415:75-85; PMID: 14600595; DOI: 10.1097/01.blo. 0000093048.96273.aa.
14. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, et al. Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des 2010; 16:2981-7; PMID: 20722622; DOI: 10.2174/138161210793563554.
15. Cabrespine A, Bay JO, Verrelle P, Morel L. Interleukin-6 implication in prostate cancer. Bull Cancer 2007; 94:29-34; PMID: 17845991.
16. Cross NA, Papageorgiou M, Eaton CL. Bone marrow stromal cells promote growth and survival of prostate cancer cells. Biochem Soc Trans 2007; 35:698-700; PMID: 17635126; DOI: 10.1042/BST0350698.
17. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, et al. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3 and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003; 305:462-9; PMID: 12763015; DOI: 10.1016/S0006-291X(03) 00792-7.
18. Aaronson DS, Muller M, Neves SR, Chung WC, Jayaram G, Iyengar R, et al. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol Cell Endocrinol 2007; 270:50-6; PMID: 17374439; DOI: 10.1016/j.mce.2007.02.006.
19. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 2009; 16:155-69; PMID: 19011039; DOI: 10.1677/ERC-08-0174.
20. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63:2206-15; PMID: 12727841.
21. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 1991; 88:3720-4; PMID: 1827203; DOI: 10.1073/pnas.88.9.3720.
22. Persengiev SP, Green MR. The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis 2003; 8:225-8; PMID: 12766482; DOI: 10.1023/A:1023633704132.
23. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41:2449-61; PMID: 16199154; DOI: 10.1016/j.ejca.2005.08.008.
24. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3:859-68; PMID: 14668816; DOI: 10.1038/nrc1209.
25. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117:5965-73; PMID: 15564374; DOI: 10.1242/jcs.01589.
26. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, et al. NFκB and AP-1 connection: mechanism of NFκB-dependent regulation of AP-1 activity. Mol Cell Biol 2004; 24:7806-19; PMID: 15314185; DOI: 10.1128/MCB.24.17.7806-19.2004.
27. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17:1263-93; PMID: 12835716; DOI: 10.1038/sj.leu.2402945.
28. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, et al. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 2008; 68:2132-44; PMID: 18381418; DOI: 10.1158/0008-5472.CAN-07-6055.
29. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate 2008; 68:924-34; PMID: 18386285; DOI: 10.1002/pros.20737.
30. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res 2010; 70:4560-8; PMID: 20460526; DOI: 10.1158/0008-5472.CAN-09-3596.
31. Kajanne R, Miettinen P, Tenhunen M, Leppä S. Transcription factor AP-1 promotes growth and radio-resistance in prostate cancer cells. Int J Oncol 2009; 35:1175-82; PMID: 19787273.
32. Zerbini LF, Libermann TA. Life and death in cancer. GADD45 alpha and gamma are critical regulators of NFkappaB mediated escape from programmed cell death. Cell Cycle 2005; 4:18-20; PMID: 15613850; DOI: 10.4161/cc.4.1.1363.
33. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, Ijiri K, et al. NFκB-mediated repression of growth arrest-and DNA-damage-inducible proteins 45α and γ is essential for cancer cell survival. Proc Natl Acad Sci USA 2004; 101:13618-23; PMID: 15353598; DOI: 10.1073/pnas.0402069101.
34. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 1998; 95:521-30; PMID: 9827804; DOI: 10.1016/S0092-8674(00)81619-0.
35. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, et al. Induction of gadd45β by NFκB downregulates pro-apoptotic JNK signalling. Nature 2001; 414:308-13; PMID: 11713530; DOI: 10.1038/35104560.
36. Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M. Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol Cell Biol 1995; 15:3748-58; PMID: 7791782.
37. Thépot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babinet C, et al. Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development 2000; 127:143-53; PMID: 10654608.
38. Deng T, Karin M. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev 1993; 7:479-90; PMID: 8383624; DOI: 10.1101/gad.7.3.479.
39. Shin S, Asano T, Yao Y, Zhang R, Claret FX, Korc M, et al. Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. Mol Cancer Res 2009; 7:745-54; PMID: 19435822; DOI: 10.1158/1541-7786.MCR-08-0462.
40. Li R, Pei H, Watson DK. Regulation of Ets function by protein - protein interactions. Oncogene 2000; 19:6514-23; PMID: 11175367; DOI: 10.1038/sj.onc.1204035.
41. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y, et al. aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci USA 2009; 106:16369-74; PMID: 19805306; DOI: 10.1073/pnas.0907044106.
42. Yazgan O, Pfarr CM. Regulation of two JunD isoforms by Jun N-terminal kinases. J Biol Chem 2002; 277:29710-8; PMID: 12052834; DOI: 10.1074/jbc.M204552200.
43. Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 1999; 104:503-13; PMID: 10449442; DOI: 10.1172/JCI7094.
44. Zerbini LF, Wang Y, Correa RG, Cho JY, Libermann TA. Blockage of NFkappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 2005; 4:1247-53; PMID: 16082226; DOI: 10.4161/cc.4.9.1966.
45. Li W, Zhang X, Olumi AF. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L). Cancer Res 2007; 67:2247-55; PMID: 17332355; DOI: 10.1158/0008-5472.CAN-06-3793.
46. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67:9425-34; PMID: 17909052; DOI: 10.1158/0008-5472.CAN-07-1310.
47. Zhang X, Huang X, Olumi AF. Repression of NFκB and Activation of AP-1 Enhance Apoptosis in Prostate Cancer Cells. Int J Cancer 2009; 124:1980-9; PMID: 19123467; DOI: 10.1002/ijc.24139.
48. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, et al. IL (interleukin)-1a promotes nuclear factor-Kb and AP-1-induced IL-8 expression, cell survival and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001; 7:1812-20; PMID: 11410524.
49. Zerbini LF, Czibere A, Wang Y, Correa RG, Otu H, Joseph M, et al. A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res 2006; 66:11922-31; PMID: 17178890; DOI: 10.1158/0008-5472.CAN-06-2068.
50. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 2002; 99:10054-9; PMID: 12114539; DOI: 10.1073/pnas.152327199.